Laliberté Camille, Bossé Bianca, Bourdeau Véronique, Prieto Luis I, Perron-Deshaies Genève, Vuong-Robillard Nhung, Igelmann Sebastian, Aguilar Lisbeth Carolina, Oeffinger Marlene, Baker Darren J, DesGroseillers Luc, Ferbeyre Gerardo
Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC H3C 3J7, Canada.
Centre de Recherche du Centre, Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada.
Biomedicines. 2024 May 14;12(5):1089. doi: 10.3390/biomedicines12051089.
Senescent cells, which accumulate with age, exhibit a pro-inflammatory senescence-associated secretory phenotype (SASP) that includes the secretion of cytokines, lipids, and extracellular vesicles (EVs). Here, we established an in vitro model of senescence induced by Raf-1 oncogene in RAW 264.7 murine macrophages (MΦ) and compared them to senescent MΦ found in mouse lung tumors or primary macrophages treated with hydrogen peroxide. The transcriptomic analysis of senescent MΦ revealed an important inflammatory signature regulated by NFkB. We observed an increased secretion of EVs in senescent MΦ, and these EVs presented an enrichment for ribosomal proteins, major vault protein, pro-inflammatory miRNAs, including miR-21a, miR-155, and miR-132, and several mRNAs. The secretion of senescent MΦ allowed senescent murine embryonic fibroblasts to restart cell proliferation. This antisenescence function of the macrophage secretome may explain their pro-tumorigenic activity and suggest that senolytic treatment to eliminate senescent MΦ could potentially prevent these deleterious effects.
衰老细胞会随着年龄的增长而积累,表现出一种促炎性衰老相关分泌表型(SASP),其中包括细胞因子、脂质和细胞外囊泡(EVs)的分泌。在此,我们建立了一种由Raf-1癌基因诱导RAW 264.7小鼠巨噬细胞(MΦ)衰老的体外模型,并将其与在小鼠肺肿瘤中发现的衰老MΦ或用过氧化氢处理的原代巨噬细胞进行比较。对衰老MΦ的转录组分析揭示了一种由NFkB调节的重要炎症特征。我们观察到衰老MΦ中EVs的分泌增加,并且这些EVs富含核糖体蛋白、主要穹窿蛋白、促炎性miRNA,包括miR-21a、miR-155和miR-132,以及几种mRNA。衰老MΦ的分泌使衰老的小鼠胚胎成纤维细胞重新开始细胞增殖。巨噬细胞分泌组的这种抗衰老功能可能解释了它们的促肿瘤活性,并表明消除衰老MΦ的衰老细胞溶解疗法可能潜在地预防这些有害影响。
Arch Biochem Biophys. 2024-4
World J Gastroenterol. 2014-12-21
Cancer Biol Med. 2025-5-6
Front Aging. 2025-3-28
Cardiovasc Res. 2025-5-23
Cancer Cell. 2023-7-10
Cancer Cell. 2023-7-10
Nat Med. 2022-8
Nature. 2020-6-17
Adv Drug Deliv Rev. 2020